YMTHE, Volume 25

# **Supplemental Information**

## **Cut and Paste: Efficient Homology-Directed**

#### Repair of a Dominant Negative KRT14

## Mutation via CRISPR/Cas9 Nickases

Thomas Kocher, Patricia Peking, Alfred Klausegger, Eva Maria Murauer, Josefina Piñón Hofbauer, Verena Wally, Thomas Lettner, Stefan Hainzl, Michael Ablinger, Johann Wolfgang Bauer, Julia Reichelt, and Ulrich Koller

#### **Supplementary Data**

#### **HEK 293**

sgRN	A1	3'ggaggagacgtccggacccg 5'						
localization		target sequence	Cas9n/sgRNA1+2		spCas9/sgRNA1		A1	
on-target sgRNA1		on-target sgRNA1	PAM+2	PAM+3	PAM+4	PAM+2	PAM+3	PAM+4
Chr. 1	17 (41583086 to 41583064) KRT14 Intron 7 (sense)	5'cctcctcctgcaggcctgggc 3'	0,31	0,31	0,24	3,38	6,56	16,10
off-targets sgRNA1		off-targets sgRNA1 PAM+		PAM+/- 3	PAM+/- 4	PAM+/- 2	PAM+/- 3	PAM+/-4
Chr. 4	4 (1738178 to 1738200) TACC3 Intron 10 (sense)	5'ccccctctctgcaggcctgggc 3'	0,00	0,00	0,00	0,00	0,00	4,37
Chr. 2	21 (26917895 to 26917917) APP Intron 7 (antisense)	3 ctacataattcgtctcctcctcc 5	0,35	0,17	0,00	0,23	0,05	0,00
Chr. 2	21 (44907189 to 44907211) ITGB2 Intron 4 (antisense)	3'ttaaggtccgcgtctcctcctcc 5'	0,15	0,37	0,37	0,00	0,00	0,00
Chr. 1	17 (2787805 to 2787827) RAP1GAP2 Intron 2 (sense)	5'cctcctcctgctggccttccac 3'	0,00	0,00	0,16	0,00	0,00	2,50
Chr. 2	21 (42294475 to 42294497) ABCG1 Intron 14 (sense)	5'gagcctcctctgcaggaggccag 3'	0,00	0,00	0,00	0,00	0,00	0,00
Chr. 2	21 (44724272 to 44724294) PDXK Intron 4 (sense)	5'cttcctcctctgcacgcctccgt 3'	0,08	0,00	0,00	0,87	0,00	0,00
Chr. 2	21 (40725550 to 40725572) IGSF5 Intron 7 (sense)	5'actcctcctctgcaggatgaaca 3'	0,00	0,00	0,07	0,13	0,06	0,00
Chr. 2	21 (36962293 to 36962315) HLCS Intron 1 (antisense)	3 gatgctcctctgcaggccgcagg 5	0,30	0,00	0,00	0,47	0,00	0,00
sgRN	A2	5 agcaggtctaggcattggct 3						
locali	zation	target sequence	Ca	s9n/sgRNA1	+2	sp	Cas9/sgRN	A2
on-tai	rget sgRNA2	on-target sgRNA2	PAM-2	PAM-3	PAM-4	PAM-2	PAM-3	PAM-4
Chr. 1	17 (41583040 to 41583018) KRT14 Intron 7 (antisense)	3'tcgtccagatccgtaaccgatcc 5'	0,00	0,00	0,00	0,00	1,84	28,65
off-ta	rgets sgRNA2	off-targets sgRNA2	PAM+/- 2	PAM+/- 3	PAM+/- 4	PAM+/- 2	PAM+/- 3	PAM+/-4
Chr. 1	11 (2936955 to 2936977) SLC22A18 Intron 6 (antisense)	3 ccgttaccttccgtaaccgatcc 5	0,00	0,00	0,00	0,00	0,00	0,00
Chr. 4	4 (67871082 to 67871104) TMPRSS11D Intron 1 (sense)	5'cctagccaatgccttcctaggaa 3'	0,00	0,00	0,00	0,20	0,09	0,43
Chr. 4	4 (113999328 to 113999350) ANK2 Intron 1 (antisense)	3'cttaataaacccgtaaccgatcc 5'	0,00	0,00	0,00	0,28	0,23	0,00
Chr. 1	11 (52028437 to 52028459) AAMDC Intron 3 (antisense)	3'accccaatatccgtaaccgattt 5'	0,00	0,00	0,00	0,03	0,00	0,00
Chr. 5	5 (36657983 to 36658005) SLC1A3 Intron 3 (antisense)	3'acttagatatccgtaaccgatta 5'	0,12	0,04	0,00	0,00	0,03	0,00

Supplementary Table 1: DNA cleavage activity of the respective nucleases at potential off-target regions for sgRNA1 and sgRNA2. DNA cleavage activities of sgRNAs at on-target and off-target regions are represented as % indels relative to untreated control. The cut-off for cleavage activity was set to 0.5%. Colored boxes indicate cleavage activity of the respective Cas9/sgRNA at on-target and off-target regions. On-target and off-target regions entry indicating mismatches between the sgRNA on-target binding sites and the potential off-target regions and black letters indicating matches between on-target and off-target regions.



**Supplementary Figure 1: Schematic depiction of on-target and off-target cutting sites.** DNA cleavage sites of the two sgRNAs at on-target and predicted off-target regions are shown, with orange letters indicating the PAM position, red letters indicating mismatches between the sgRNA on-target binding sites and the potential off-target regions and blue letters indicating matches between on-target and off-target regions. Two predicted off-targets are depicted for each sgRNA, showing either antisense strand or sense strand targeting.



**Supplementary Figure 2: Transfection efficiency and selection efficiency using a MC donor plasmid. (A)** Size comparison of the parental MC donor plasmid (MCp-DP) and the MC donor plasmid. (B) Flow cytometric analysis of EBS-gen sev keratinocytes 48 hours post transfection revealed differences in transfection efficiencies. (C) Selection and sorting strategy for the different CRISPR/Cas9 gene editing approaches. Representative FACS blots show (a) untreated patient cells, treated cells (b) after transfection with the MC DP, (c) after blasticidin selection stop.



Supplementary Figure 3: Correction of the dominantly inherited missense mutation (c.1231G>A) within exon 6 of *KRT14* gene in single cell clones. (A) Amplification of endogenous *KRT14* using a forward primer binding to exon 3 and a reverse primer binding exon 7 and the integrated restriction sites (EcoRI and NheI sequence). Correction of the mutation within exon 6 of *KRT14* was confirmed by sequence analysis of the PCR product. Red star: heterozygous mutation (A>G) within exon 6; green star: repaired mutation (A>G) within exon 6 of targeted allele. (B) Amplification of expressed *KRT14* (cDNA) using a forward primer binding to the exon 5/exon 6 junction and a reverse primer binding to exon 8. Correction of the mutation of the mutation (position 164); R indicates the heterozygous mutation. G indicates correction of the mutation. blue stars: silent mutations. (C) Sequence analysis of the predicted off-target region intron 10 of *TACC3*. The predicted off-target region for sgRNA1 was PCR-amplified using a primer pair binding specifically within *TACC3* intron 10. Genomic DNA isolated from single cell clones treated with Cas9n-sgRNA1+2/ MC–DP and untreated EBS keratinocytes was used as PCR template. PAM +22/23 represents positions of typical on-target indel formations within intron 7 of *KRT14* via double nicking. Sequence alignment was performed with the software "Multiple sequence alignment with hierarchical clustering" (21).

localization	HEK293 (mean coverage; reads)	EBS hKc (mean coverage; reads)	forward primer	reverse primer
on-target	on-target	on-target	on-target	on-target
KRT14 Intron 7	1847	10075	5'- ACCATGTATCTAATGATCCTGTCCTTTTCTA -3'	5'- CTCAGCCCCTCACGGAG -3'
off-targets sgRNA1	off-targets sgRNA1	off-targets sgRNA1	off-targets sgRNA1	off-targets sgRNA1
TACC3 Intron 10	2043	6629	5'- CCAACATCCACACCAGTGTTGT -3'	5'- GGCACCCTTTCTGCAGAAAGTA -3'
APP Intron 7	1041	4549	5'- GGAAGGAAGGAAGGAAAGAGTCATG -3'	5'- GCACTCTTCTACCAAAACATTTTCAGT -3'
ITGB2 Intron 4	462	2172	5'- CCATTGTGGTCTTCCTGGGTTT -3'	5'- CTAGAGGCAGAGGAGGAGGCGATA -3'
RAP1GAP2 Intron 2	1312	4335	5'- GCTCATGTAGCAAGTGGCTTCA -3'	5'- GGGAAGGCTACAGGAAGGATGA -3'
ABCG1 Intron 14	450	1638	5'- GCAGACGGCAGTCTGTTGAG -3'	5'- GAAAGTGGCCACCTGGAGTT -3'
PDXK Intron 4	954	2827	5'- CCCTAAAGGTTATACGAGGGACAAGT -3'	5'- CCACTATACGAGCACACTGACA -3'
IGSF5 Intron 7	1367	4819	5'- GGAATGCTGGAAAACTAGACCTACT -3'	5'- ATGCAATCTGGAATACACATGGGA -3'
HLCS Intron 1	599	2273	5'- GTTCTGCTTCAAGTATAAAAGGAGACACA -3'	5'- CCGGTTAGCTACTGTGTGCTAA -3'
off-targets sgRNA2	off-targets sgRNA2	off-targets sgRNA2	off-targets sgRNA2	off-targets sgRNA2
SLC22A18 Intron 6	2711	2053	5'- GTCCTCAGCTTCACCTGCAT -3'	5'- CACTTGGCTTCTATGATGTCAGCA -3'
TMPRSS11D Intron 1	2084	4277	5'- TTATCTGTCTCCCTCCACCAGTT -3'	5'- TGAAAGGGAAACACTTTGAGTTTCTTTAAA -3'
ANK2 Intron 1	1111	2550	5'- AAGTACACATGCAAGCCCTGAA -3'	5'- TCCCTGAGTCTTATAAATTTTTCCACCAAA -3'
AAMDC Intron 3	2477	2962	5'- CCGGCTATCCTCCAAATTCTTAACA -3'	5'- TGTTACCTGGATGTGAGACATGGA -3'
SLC1A3 Intron 3	3972	5858	5'- GCTACCAGTTGCAGCATTGACT -3'	5'- GTGAGAATGCCATCATTTGACCAAG -3'

Supplementary Table 2: NGS primer combinations and mean coverage of the designed panel.